These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 28390291

  • 1. Soluble TWEAK and atheromatosis progression in patients with chronic kidney disease.
    Fernández-Laso V, Méndez-Barbero N, Valdivielso JM, Betriu A, Fernández E, Egido J, Martín-Ventura JL, Blanco-Colio LM.
    Atherosclerosis; 2017 May; 260():130-137. PubMed ID: 28390291
    [Abstract] [Full Text] [Related]

  • 2. Soluble TWEAK and Major Adverse Cardiovascular Events in Patients with CKD.
    Fernández-Laso V, Sastre C, Valdivielso JM, Betriu A, Fernández E, Egido J, Martín-Ventura JL, Blanco-Colio LM.
    Clin J Am Soc Nephrol; 2016 Mar 07; 11(3):413-22. PubMed ID: 26728587
    [Abstract] [Full Text] [Related]

  • 3. Soluble TWEAK levels predict the presence of carotid atherosclerotic plaques in subjects free from clinical cardiovascular diseases.
    Fernández-Laso V, Sastre C, Valdivielso JM, Fernández E, Martín-Ventura JL, Egido J, Blanco-Colio LM.
    Atherosclerosis; 2015 Apr 07; 239(2):358-63. PubMed ID: 25681674
    [Abstract] [Full Text] [Related]

  • 4. Soluble TWEAK is associated with atherosclerotic burden in patients with chronic kidney disease.
    Valdivielso JM, Coll B, Martín-Ventura JL, Moreno JA, Egido J, Fernández E, Blanco-Colio LM.
    J Nephrol; 2013 Apr 07; 26(6):1105-13. PubMed ID: 23475462
    [Abstract] [Full Text] [Related]

  • 5. Combination of biomarkers of vascular calcification and sTWEAK to predict cardiovascular events in chronic kidney disease.
    Bozic M, Méndez-Barbero N, Gutiérrez-Muñoz C, Betriu A, Egido J, Fernández E, Martín-Ventura JL, Valdivielso JM, Blanco-Colio LM, investigators from the NEFRONA study.
    Atherosclerosis; 2018 Mar 07; 270():13-20. PubMed ID: 29407881
    [Abstract] [Full Text] [Related]

  • 6. Circulating angiotensin converting enzyme 2 activity as a biomarker of silent atherosclerosis in patients with chronic kidney disease.
    Anguiano L, Riera M, Pascual J, Valdivielso JM, Barrios C, Betriu A, Clotet S, Mojal S, Fernández E, Soler MJ, investigators from the NEFRONA study.
    Atherosclerosis; 2016 Oct 07; 253():135-143. PubMed ID: 27615597
    [Abstract] [Full Text] [Related]

  • 7. Predictors of Subclinical Atheromatosis Progression over 2 Years in Patients with Different Stages of CKD.
    Gracia M, Betriu À, Martínez-Alonso M, Arroyo D, Abajo M, Fernández E, Valdivielso JM, NEFRONA Investigators.
    Clin J Am Soc Nephrol; 2016 Feb 05; 11(2):287-96. PubMed ID: 26668022
    [Abstract] [Full Text] [Related]

  • 8. Relationship between low levels of circulating TRAIL and atheromatosis progression in patients with chronic kidney disease.
    Arcidiacono MV, Rimondi E, Maietti E, Melloni E, Tisato V, Gallo S, Valdivielso JM, Fernández E, Betriu À, Voltan R, Zauli G, Volpato S, Secchiero P.
    PLoS One; 2018 Feb 05; 13(9):e0203716. PubMed ID: 30204795
    [Abstract] [Full Text] [Related]

  • 9. Association of FGF-2 Concentrations with Atheroma Progression in Chronic Kidney Disease Patients.
    Bozic M, Betriu A, Bermudez-Lopez M, Ortiz A, Fernandez E, Valdivielso JM, NEFRONA investigators.
    Clin J Am Soc Nephrol; 2018 Apr 06; 13(4):577-584. PubMed ID: 29519952
    [Abstract] [Full Text] [Related]

  • 10. Observational multicenter study to evaluate the prevalence and prognosis of subclinical atheromatosis in a Spanish chronic kidney disease cohort: baseline data from the NEFRONA study.
    Arroyo D, Betriu A, Martinez-Alonso M, Vidal T, Valdivielso JM, Fernández E, investigators from the NEFRONA study.
    BMC Nephrol; 2014 Oct 18; 15():168. PubMed ID: 25326683
    [Abstract] [Full Text] [Related]

  • 11. Soluble TWEAK level: is it a marker for cardiovascular disease in long-term hemodialysis patients?
    Gungor O, Kircelli F, Asci G, Carrero JJ, Tatar E, Demirci MS, Ozbek SS, Ceylan N, Toz H, Ozkahya M, Ok E.
    J Nephrol; 2013 Oct 18; 26(1):136-43. PubMed ID: 22505251
    [Abstract] [Full Text] [Related]

  • 12. Association of the rs495392 Klotho polymorphism with atheromatosis progression in patients with chronic kidney disease.
    Valdivielso JM, Bozic M, Galimudi RK, Bermudez-López M, Navarro-González JF, Fernández E, Betriu À.
    Nephrol Dial Transplant; 2019 Dec 01; 34(12):2079-2088. PubMed ID: 30010839
    [Abstract] [Full Text] [Related]

  • 13. Association of serum phosphorus with subclinical atherosclerosis in chronic kidney disease. Sex makes a difference.
    Martín M, Valls J, Betriu A, Fernández E, Valdivielso JM.
    Atherosclerosis; 2015 Jul 01; 241(1):264-70. PubMed ID: 25748053
    [Abstract] [Full Text] [Related]

  • 14. Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease.
    Yilmaz MI, Carrero JJ, Ortiz A, Martín-Ventura JL, Sonmez A, Saglam M, Yaman H, Yenicesu M, Egido J, Blanco-Colio LM.
    Clin J Am Soc Nephrol; 2009 Nov 01; 4(11):1716-23. PubMed ID: 19820131
    [Abstract] [Full Text] [Related]

  • 15. Soluble TWEAK may predict carotid atherosclerosis in treated HIV infection.
    Dirajlal-Fargo S, Sattar A, Kulkarni M, Funderburg N, McComsey GA.
    HIV Clin Trials; 2017 Jul 01; 18(4):156-163. PubMed ID: 28828963
    [Abstract] [Full Text] [Related]

  • 16. Changes in Soluble TWEAK Concentrations, but Not Those in Amyloid-β(1-40), Are Associated with a Decrease in Carotid Intima-Media Thickness after Bariatric Surgery in Obese Women.
    Gómez-Martin JM, Aracil E, Insenser M, de la Peña G, Lasunción MA, Galindo J, Escobar-Morreale HF, Balsa JA, Botella-Carretero JI.
    Obes Facts; 2020 Jul 01; 13(3):321-330. PubMed ID: 32388504
    [Abstract] [Full Text] [Related]

  • 17. Serum pentraxin-3 and tumor necrosis factor-like weak inducer of apoptosis (TWEAK) predict severity of infections in acute decompensated cirrhotic patients.
    Fan WC, Huang CC, Yang YY, Lin A, Lee KC, Hsieh YC, Fung CP, Hsu HC, Hou MC, Lin HC.
    J Microbiol Immunol Infect; 2017 Dec 01; 50(6):905-914. PubMed ID: 26872435
    [Abstract] [Full Text] [Related]

  • 18. Diabetic nephropathy is an independent factor associated to severe subclinical atheromatous disease.
    Barrios C, Pascual J, Otero S, Soler MJ, Rodríguez E, Collado S, Faura A, Mojal S, Navarro-González JF, Betriu A, Fernandez E, Valdivielso JM, investigators of the NEFRONA study.
    Atherosclerosis; 2015 Sep 01; 242(1):37-44. PubMed ID: 26177272
    [Abstract] [Full Text] [Related]

  • 19. The relationships between serum sTWEAK, FGF-23 levels, and carotid atherosclerosis in renal transplant patients.
    Gungor O, Kismali E, Sisman AR, Kircelli F, Carrero JJ, Tatar E, Asci G, Toz H.
    Ren Fail; 2013 Sep 01; 35(1):77-81. PubMed ID: 23101788
    [Abstract] [Full Text] [Related]

  • 20. Brain natriuretic peptide is related to carotid plaques and predicts atherosclerosis in pre-dialysis patients with chronic kidney disease.
    Zhou W, Ni Z, Yu Z, Shi B, Wang Q.
    Eur J Intern Med; 2012 Sep 01; 23(6):539-44. PubMed ID: 22863432
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.